Streamlined mAb Subunit LC-MS Workflow for Multiple Attribute Monitoring of Biosimilar mAb Candidates During Bioprocessing and Development

RECORD | Already taken place Th, 12.10.2023

Hear a customer perspective on deploying Waters solutions to enhance biosimilar development.

Waters Corporation: "Hear a customer perspective on deploying Waters solutions to enhance biosimilar development: Streamlined mAb Subunit LC-MS Workflow for Multiple Attribute Monitoring of Biosimilar mAb Candidates During Bioprocessing and Development"

Demonstration of an automated Protein A purification and LC-MS mAb subunit analysis of bioreactor samples to screen biosimilar monoclonal antibody (mAb) candidates in comparison to the innovator to support process development.

The method was demonstrated to have sufficient sensitivity and precision to quantitively assess N-linked oligosaccharides at levels known to impact pharmacokinetics and effector function activity, in addition to other post-translational modifications (PTMs) such as C-terminal lysine variants and other subunit-specific (LC & Fd’) modifications

Presenter: Jared Young (Similis Bio)

Waters Corporation

Streamlined mAb Subunit LC-MS Workflow for Multiple Attribute Monitoring of Biosimilar mAb Candidates During Bioprocessing and Development

Related content

Simultaneous Quantitation and Discovery analysis: Combining targeted and untargeted metabolomics on Orbitrap mass spectrometers

Analysis of Per- and Polyfluoroalkyl Substances (PFAS) in Wastewater

Non-Targeted Screening of Biosolids with the Xevo™ MRT Mass Spectrometer Reveals New Isoforms of PFAS

High Resolution Characterization of Lipid Nanoparticles Using the Xevo™ Charge Detection Mass Spectrometry (CDMS) Instrument - Single Particle Mass Analysis of Intact LNP-mRNA Formulations

Out-of-the-box workflow for PFAS quantitation using a fullscan high-resolution approach with the Orbitrap Exploris EFOX Mass Detector